A5021880262- Hematopoietic Stem Cell Transplantation
- Acute Myeloid Leukemia Research
- Acute Lymphoblastic Leukemia research
- Cytomegalovirus and herpesvirus research
- Chronic Myeloid Leukemia Treatments
- Chronic Lymphocytic Leukemia Research
- Immune Cell Function and Interaction
- Polyomavirus and related diseases
- Lymphoma Diagnosis and Treatment
- T-cell and B-cell Immunology
- Mesenchymal stem cell research
- CAR-T cell therapy research
- Hematological disorders and diagnostics
- Neutropenia and Cancer Infections
- Viral-associated cancers and disorders
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Platelet Disorders and Treatments
- Immunotherapy and Immune Responses
- Antifungal resistance and susceptibility
- Renal Transplantation Outcomes and Treatments
- Eosinophilic Disorders and Syndromes
- Immunodeficiency and Autoimmune Disorders
- Fungal Infections and Studies
- RNA modifications and cancer
- Blood groups and transfusion
Chinese PLA General Hospital
2016-2025
Chongqing Cancer Hospital
2022-2025
Chongqing University
2022-2025
Peking University
2008-2024
Peking University People's Hospital
2008-2024
Nankai University
2023-2024
People's Liberation Army No. 150 Hospital
2016-2023
Xiangya Hospital Central South University
2023
Central South University
2023
PLA Academy of Military Science
2022-2023
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains one of the best therapeutic options to cure acute leukemia (AL). However, many patients have no human leukocyte antigen (HLA)-matched donor. Recently, we developed a new method for HLA-mismatched/haploidentical without in vitro T depletion (TCD). This combined granulocyte-colony stimulating factor (G-CSF)-primed bone marrow and peripheral blood with intensive immunosuppression. We analyzed outcome 250 consecutive AL who...
Abstract BACKGROUND: Many patients who require allogeneic hematopoietic stem cell transplantation (allo‐HSCT) lack a human leukocyte antigen (HLA)‐matched donor. Recently, new strategy was developed for HLA‐mismatched/haploidentical from family donors without in vitro T depletion (TCD). METHODS: Over the past 9 years, 756 underwent haploidentical using protocol by authors, which combines granulocyte‐colony stimulating factor–primed bone marrow (G‐BM) and peripheral blood cells TCD. The...
Abstract The consensus recommendations in 2018 from Chinese Society of Hematology (CSH) on indications, conditioning regimens and donor selection for allogeneic hematopoietic stem cell transplantation (allo-HSCT) facilitated the standardization clinical practices allo-HSCT China progressive integration with world. There have been new developments since initial publication. To integrate recent further improve consensus, a panel experts CSH recently updated recommendations, which are...
The outcomes of an historic comparison 117 consecutive, high-risk, acute leukemia patients undergoing hematopoietic stem cell transplantation (HSCT) from HLA-mismatched/haploidentical donors (HID, n = 81) or HLA-identical sibling (ISD, 36) without the use in vitro T depletion (TCD), between period January 2005 and April 2009 were compared. Full engraftment was achieved 98% HID group 97% ISD group. cumulative incidences grades II-IV graft-versus-host disease (aGVHD) cohorts 49% 24%,...
Mesenchymal stromal cells (MSCs) are attractive agents for the prophylaxis of acute graft-versus-host disease (aGVHD) after allogeneic hematopoietic stem cell transplantation (allo-HSCT). However, safety concerns remain about their clinical application. In this study, we explored whether extracellular vesicles released from human umbilical cord-derived MSCs (hUC-MSC-EVs) could prevent aGVHD in a mouse model allo-HSCT. hUC-MSC-EVs were intravenously administered to recipient mice on days 0...
Poor graft function (PGF) is a serious complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Whether abnormalities of the bone marrow (BM) microenvironment are involved in pathogenesis PGF unclear. In present prospective nested case-control study, 19 patients with secondary PGF, 38 matched good (GGF) allo-HSCT, and 15 healthy donors (HDs) were enrolled. The cellular elements BM microenvironment, including endosteal cells, perivascular vascular analyzed by flow...
Abstract Between 2008 and 2019, 58,914 hematopoietic stem cell transplantations (HSCTs) were reported to the Chinese Blood Marrow Transplantation Registry Group (CBMTRG) throughout China. In this report, we focus on 2019 data describe current trends in HSCT There was continued growth transplant activity China, with a rapid increase haploidentical HSCT. total of 12,323 cases from 149 teams, 78% (9597 cases) allogeneic HSCTs. Haploidentical donor (HID) accounted for 60% (5771 The most common...
Background Cytomegalovirus (CMV) reactivation after unmanipulated haploidentical stem cell transplantation (SCT) frequently occurs, causing life-threatening morbidities and failure. Pre-emptive therapy upon the detection of CMV viremia using antiviral agents is currently standard care but it was associated with significant toxicity. The antigen-specific cytotoxic T lymphocyte limited by time-consuming manufacture process relatively low success rate. More effective safer approaches for...
The study aimed to compare the outcomes of patients undergoing hematopoietic stem cell transplantation (HSCT) from partially matched related donors (PMRD) and unrelated (URD) for hematologic malignancies without use in vitro T depletion.HSCT was done on 297 consecutive URDs (n = 78) PMRDs 219) during same time period. Incidences graft-versus-host disease (GVHD), relapse, nonrelapse mortality, overall survival, leukemia-free survival between PMRD URD groups were compared.All achieved full...
Abstract Background Maintenance therapy with imatinib during the post-transplant period has been used for patients Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph + ALL); however, its efficacy not demonstrated. A study was designed to investigate safety of and in preventing hematological relapse improving disease-free survival (DFS) when administered after allogeneic hematopoietic stem cell transplantation (allo-HCT). Methods Patients Ph ALL that received allo-HCT were...
Abstract Steroid‐refractory (SR) acute graft‐versus‐host disease (aGVHD) is one of the leading causes early mortality after allogeneic hematopoietic stem cell transplantation (allo‐HSCT). We investigated efficacy, safety, prognostic factors, and optimal therapeutic protocol for SR‐aGVHD patients treated with basiliximab in a real‐world setting. Nine hundred forty were recruited from 36 hospitals China, 3683 doses administered. Basiliximab was used as monotherapy ( n = 642) or combination...
Previous studies have suggested that mesenchymal stromal cells (MSCs) enhance the engraftment of hematopoietic stem and modulate host's immune response. However, there are no randomized to confirm these results. Moreover, some concerns about risk tumor recurrence because immunosuppressive property MSCs. We conducted an open-label, phase II clinical study assess outcome MSC coinfusion (3-5 × 10(5) cells/kg) during haploidentical cell transplantation. From June 2007 2008, a total 55 patients...